Drug Type Antibody drug conjugate (ADC) |
Synonyms PBX 003, PBX003 |
Target |
Action modulators, inhibitors |
Mechanism EGFR modulators(Epidermal growth factor receptor erbB1 modulators), TOP1 inhibitors(DNA topoisomerase I inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Colorectal Cancer | Preclinical | South Korea | 11 Jan 2024 | |
| Head and Neck Neoplasms | Preclinical | South Korea | 11 Jan 2024 | |
| Lung Cancer | Preclinical | South Korea | 11 Jan 2024 | |
| Pancreatic Cancer | Discovery | South Korea | 07 Jun 2023 |






